Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys LLY Stock

Democratic Representative Gilbert Ray Cisneros Jr. added to his portfolio with a stock purchase of Eli Lilly and Company LLY, according to a periodic transaction report filed with the House. The trade, executed on June 10, 2026, and disclosed on July 2, 2026, carried a value between $50,001 and $100,000.

Inside Gilbert Ray Cisneros Jr.'s Eli Lilly Trade

Under the rules of the STOCK Act, members of Congress report their personal stock transactions within designated windows, though disclosures show broad financial ranges instead of exact purchase amounts. The transaction for Eli Lilly shares occurred on June 10, 2026, when the stock closed at $1,134.74. The filing does not disclose the precise share count or execution price, but places the total value of the acquired stake in the $50,001 to $100,000 bracket.

Other Institutional Activity in Eli Lilly

Large institutional investors made adjustments to their holdings in the pharmaceutical company around the middle of the year. Lilly Endowment, Inc reduced its holdings by 1,516,238 shares, ending with 90,376,978 shares worth about $113,606,575,303. Blackrock Inc. grew its holdings by 1,161,629 shares, ending with 67,540,400 shares worth about $84,900,310,990. Vanguard Capital Management LLC grew its holdings by 165,427 shares, ending with 53,528,868 shares worth about $67,287,394,510. PNC Financial Services Group, Inc. reduced its holdings by 5,133 shares, ending with 51,322,720 shares worth about $64,514,200,225. State Street Corporation grew its holdings by 605,376 shares, ending with 36,215,754 shares worth about $45,524,290,311.

Eli Lilly and Company Stock Up 3.8%

Eli Lilly shares recently traded around $1,254.96 as of October 16, 2026, sitting up about 10.6% since the lawmaker's June transaction date. The stock trades above its 50-day moving average of $1,179.04 and above its 200-day moving average of $1,079.02. Over the past year, the shares have changed hands within a 52-week range of $783.85 to $1,292.65.

Recent Earnings

The company reported trailing twelve-month revenue of $79,666,003,968 alongside earnings of $29.79 per share. The business maintains a net profit margin of 33.5% and a return on equity of 102.3%. Investors can look ahead to the company's upcoming earnings report on October 29, 2026, for fresh financial details.

Dividend

Eli Lilly pays an annual dividend yielding 0.55% backed by a dividend payout ratio of 21.7%.

Insider Buying and Selling at Eli Lilly and Company

Company insiders executed several stock sales over the summer months. Officer Ilya Yuffa sold 2,500 shares on June 10, 2026, at a price of $1,150.77 for a total value of $2,876,925. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at a price of $1,190.00 for a total value of $5,950,000. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, at a price of $1,185.01 for a total value of $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at a price of $1,175.10 for a total value of $7,638,150.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock following recent reports. On August 7, 2026, Truist Securities maintained a buy rating with a target of $1,376.00. HSBC maintained a reduce rating with a target of $940.00 on September 10, 2026. Guggenheim maintained a buy rating with a target of $1,284.00 on September 18, 2026. TD Cowen reiterated a buy rating with a target of $1,250.00 on September 22, 2026. JP Morgan maintained an overweight rating with a target of $1,500.00 on September 28, 2026. Across the analyst community, the stock holds a consensus buy rating with a mean price target of $1,328.05 based on 30 analyst opinions.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products globally. Headquartered in Indianapolis, Indiana, the health care firm focuses on drug manufacturing in major therapeutic areas. Congressional trades in pharmaceutical companies often draw attention due to ongoing legislative debates surrounding drug pricing, health care policy, and federal research funding.

Bottom Line

Market participants will be watching the upcoming earnings release on October 29, 2026, for updates on treatment demand and financial results. Monitoring legislative disclosures helps track portfolio adjustments made by members of Congress over time.